Pharmaceutical intermediates
Imatinib Intermediates
3 pharmaceutical intermediates for Imatinib. Indication: Chronic Myeloid Leukemia (CML); Acute Lymphoblastic Leukemia (ALL); Hypereosinophilic Syndrome (HES); Myelodysplastic-Myeloproliferative Neoplasms; Chronic Eosinophilic Leukemia (CEL); Myelodysplastic Syndrome (MDS); Dermatofibrosarcoma Protuberans; Systemic Mastocytosis; Chronic Myelogenous Leukemia (CML); Gastrointestinal Stromal Tumor (GIST).
About Imatinib
- Originator
- Novartis Pharmaceuticals Corp
- Indication
- Chronic Myeloid Leukemia (CML); Acute Lymphoblastic Leukemia (ALL); Hypereosinophilic Syndrome (HES); Myelodysplastic-Myeloproliferative Neoplasms; Chronic Eosinophilic Leukemia (CEL); Myelodysplastic Syndrome (MDS); Dermatofibrosarcoma Protuberans; Systemic Mastocytosis; Chronic Myelogenous Leukemia (CML); Gastrointestinal Stromal Tumor (GIST)
- Approved Date
- 05/10/2001
Available intermediates
3 intermediates currently listed for Imatinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine | 152460-10-1 | / | / |
| 1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one | 55314-16-4 | / | / |
| 4-[(4-Methylpiperazin -1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3- ylpyrimidin-2-yl)amino]phenyl]benzamide | 152459-95-5 | / | / |
Building toward Imatinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →